Pelthos Therapeutics Secures $30 Million Financing to Accelerate ZELSUVMI Commercialization
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy HRZN?
Source: Globenewswire
- Financing Support: Pelthos Therapeutics secured an initial $30 million financing from Horizon, with an additional $20 million available, aimed at accelerating the commercialization of its cutaneous infectious disease product portfolio, thereby enhancing financial flexibility and market competitiveness.
- Product Launch: The financing will expedite the launch of ZELSUVMI, the first FDA-approved treatment for molluscum that can be used at home, targeting patients and families struggling with this difficult-to-treat infection.
- Equity Dilution Control: This financing is non-dilutive, as Pelthos issued warrants for 65,488 shares, ensuring existing shareholders' interests are preserved while effectively managing the company's equity structure.
- Future Growth Potential: Pelthos plans to utilize the financing to support the launch of Xepi and Xeglyze, further expanding its market share in dermatological treatments to meet the increasing patient demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HRZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HRZN
Wall Street analysts forecast HRZN stock price to rise
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 4.320
Low
6.00
Averages
6.67
High
7.50
Current: 4.320
Low
6.00
Averages
6.67
High
7.50
About HRZN
Horizon Technology Finance Corporation is a specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries. The Company's investment objective is to maximize its investment portfolio’s return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It is focused on making secured debt investments to venture capital and private equity-backed companies and publicly traded companies in its target industries. It seeks to invest in companies that vary by their stage of development, their target industries and sectors of target industries and their geographical location, as well as by the venture capital and private equity sponsors that support its portfolio companies. The Company’s adviser is Horizon Technology Finance Management LLC.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Joint Venture Formation: Horizon Technology Finance Corporation has established a new joint venture with CR Financial Holdings, committing an initial capital of $100 million to provide growth capital financing solutions for small- and micro-cap public companies in the U.S., which is expected to fill a market gap and drive business expansion.
- Clear Financing Focus: The joint venture will primarily target growth capital financing in the range of $5 million to $25 million, and with the backing of Monroe Capital, it is anticipated to attract more investor interest in financing needs of small companies, enhancing market competitiveness.
- Optimized Governance Structure: The governance of the joint venture will be managed by a four-person board and a four-person investment committee, with equal representation from Horizon and CRFH, ensuring balanced and transparent investment decisions that enhance operational efficiency.
- Significant Market Opportunity: The joint venture targets a multi-billion-dollar market opportunity, with Horizon's CEO Mike Balkin stating that it will provide compelling financing options for small- and micro-cap public companies, further driving long-term value growth for the company.
See More
- Investor Rights Investigation: The Schall Law Firm is investigating Horizon Technology Finance Corporation for potential violations of securities laws, focusing on whether the company made false or misleading statements that could harm investor interests and damage its reputation.
- Decline in Financial Performance: Horizon reported a significant drop in investment income in its Q4 and full-year 2025 financial results, primarily due to reduced prepayment activity, indicating challenges the company faces in the current market environment.
- Decrease in Net Asset Value: The company also reported a decline in net asset value per share compared to the previous quarter, raising concerns among investors regarding the company's future financial health and potentially impacting stock performance.
- Stock Price Volatility: Following the disappointing financial results, Horizon's shares plummeted by 23.3% the next day, reflecting the market's strong reaction to the company's financial condition and possibly prompting more investors to seek legal recourse.
See More
- Declining Financial Performance: Horizon Technology reported a net investment income of $0.18 per share for Q4 2025, down from $0.32 in the previous quarter and $0.27 year-over-year, indicating significant profitability pressures and weakened market confidence.
- Net Asset Value Drop: As of December 31, 2025, Horizon's net asset value per share fell to $6.98, down from $7.12 in the prior quarter and $8.43 a year earlier, reflecting deteriorating asset quality and potential financial risks.
- Stock Price Volatility: On March 4, 2026, Horizon's stock price plummeted by $1.42, or 23.32%, closing at $4.67 per share, a drastic change that may trigger investor panic and further sell-offs.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Horizon and its executives engaged in securities fraud or other unlawful business practices, which could significantly impact the company's future operations and reputation, necessitating close monitoring by investors.
See More
- Declining Financial Performance: Horizon Technology Finance Corporation reported a net investment income of $0.18 per share for Q4 2025, down from $0.32 in Q3 2025, indicating a significant deterioration in profitability that may undermine investor confidence.
- Stock Price Plunge: Following the financial disclosures, Horizon Technology's common stock fell approximately 23% the next trading day, reflecting heightened market concerns about the company's future prospects and potentially leading to further investor losses.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Horizon Technology Finance complied with federal securities laws, and if violations are confirmed, it may provide avenues for affected investors to seek compensation, thereby enhancing investor protection awareness.
- Investor Rights Advocacy: Johnson Fistel is recognized for its success in securities class actions, having recovered approximately $90.725 million for clients, showcasing its capability and influence in advocating for investor rights and compensation.
See More
- Shareholder Approval: Horizon Technology Finance (HRZN) shareholders approved the firm's share issuance proposal with over 83% support, indicating strong backing for the acquisition of Monroe Capital (MRCC), which is expected to enhance Horizon's market position.
- Monroe Vote Outcome: Monroe Capital shareholders also approved the merger and asset sale with over 88% support, demonstrating confidence in the merger and laying the groundwork for future business integration.
- Merger Details Disclosed: As previously disclosed, Monroe shareholders will receive HRZN shares equivalent to the net asset value of their MRCC shares shortly before closing, helping to ensure a balanced interest for shareholders.
- Market Reaction: Following the merger announcement, Monroe Capital's stock rose 2.2% in Monday morning trading, while Horizon Technology's stock edged up 0.1%, reflecting positive market expectations regarding the merger.
See More
- Shareholder Approval: At a special meeting on March 13, 2026, Horizon's shareholders overwhelmingly approved the HRZN Share Issuance Proposal with over 83% support, reflecting strong confidence in the merger with Monroe Capital, which is expected to unlock significant growth potential for the company.
- Asset Sale Plan: Similarly, Monroe Capital's shareholders approved the merger and asset sale with over 88% support on the same day, indicating positive market expectations for the transaction, which is anticipated to enhance the asset management capabilities of the combined entity.
- Cash Distribution Plan: Prior to the merger, MRCC plans to distribute approximately $15.9 million in cash to shareholders, further boosting shareholder confidence in the merger while laying a foundation for financial stability post-merger.
- Management Fee Waivers: Horizon's management company, HTFM, has agreed to waive $4 million in management fees over the first four full fiscal quarters following the merger, a move that will help enhance profitability and shareholder returns for the combined company.
See More











